Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Net Cash Flow (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Net Cash Flow for 17 consecutive years, with $4.8 million as the latest value for Q1 2026.

  • Quarterly Net Cash Flow rose 206.77% to $4.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Jan 2026, up 108.43% year-over-year, with the annual reading at -$35.0 million for FY2025, 96.02% down from the prior year.
  • Net Cash Flow for Q1 2026 was $4.8 million at PharmaCyte Biotech, up from $2.2 million in the prior quarter.
  • The five-year high for Net Cash Flow was $6.6 million in Q3 2023, with the low at -$17.5 million in Q3 2024.
  • Average Net Cash Flow over 5 years is -$3.9 million, with a median of -$3.2 million recorded in 2022.
  • Peak annual rise in Net Cash Flow hit 308.61% in 2023, while the deepest fall reached 1346.47% in 2023.
  • Over 5 years, Net Cash Flow stood at -$5.3 million in 2022, then surged by 76.53% to -$1.2 million in 2023, then plummeted by 854.55% to -$11.8 million in 2024, then surged by 118.89% to $2.2 million in 2025, then surged by 113.5% to $4.8 million in 2026.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $4.8 million, $2.2 million, and -$2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.